Table 6. Lifetime results of the model divided per treatment.

Parameter	LPV/r	ATV+r 1	ATV+r 2
Survival years (mean)	24.061	24.081	24.084
QALYs (mean)	13.322	13.060	13.261
Per capita mean annual cost (€)	8,477.09	8,624.77	8,548.21
Total cost (€)	203,967,086	207,693,086	205,875,090
Total cost per QALY (€)	15,310.56	15,902.99	15,524.85
Years on first-line therapy (mean)	11.711	11.143	13.466
Patients ending in first-line therapy (%)	33.43	30.92	41.12
Patients with at least 1 CHD event (%)	9.94	9.81	9.77
Patients with at least 1 CKD event (%)	41.34	58.93	63.65
Total CHD events (events per 1000 patient-years)	6.6	6.5	6.4
Total AIDS events (events per 1000 patient-years)	49.5	54.9	46.1
Total CKD events (events per 1000 patient-years)	27.1	110.9	135.3
Total OI events (events per 1000 patient-years)	35.4	35.4	35.4
Total treatment emergent AE (events per 1000 patient-years)	17.7	14.1	16.9
Two consecutive cycles with VL ≥ 50 copies/mL (events per 1000 patient-years)	17.2	20.4	14.3
Total patient-years	12,030,423	12,040,386	12,041,769
Population size	500,000	500,000	500,000

QALY: Quality-adjusted life years; CHD: Coronary heart disease; CKD: Chronic kidney disease; OI: Opportunistic infection; AE: Adverse event; VL: Viral load.